| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2024-08-07 |
| タイトル |
|
|
タイトル |
Health-related quality of life after sustained virological response to treatment for hepatitis C |
|
言語 |
en |
| 作成者 |
AKITA, Tomoyuki
KURISU, Akemi
MASUMOTO, Fumi
Bunthen, E
SUGIYAMA, Aya
KAWAOKA, Tomokazu
IMAMURA, Michio
AIKATA, Hiroshi
SEIKE, Masataka
AKUTA, Norio
KUMADA, Takashi
KARINO, Yoshiyasu
CHAYAMA, Kazuaki
TANAKA, Junko
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
Copyright (c) 2024 Hiroshima University Medical Press |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Hepatitis C |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Interferons |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Japan |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Quality of Life |
| 内容記述 |
|
|
内容記述 |
This study aimed to show the changes in health-related quality of life (HRQoL) after a sustained virological response (SVR) to hepatitis C treatment. A retrospective study was conducted among 1,546 patients with SVR to interferon-based (IFN-based) or direct-acting antiviral (DAA) anti hepatitis C virus treatments from January 1990 to March 2017 in five hospitals. The survey was conducted between November 2017 and October 2018. A questionnaire including the Japanese version of the EQ-5D-3L before and after SVR by IFN-based or DAA treatment was used to assess changes in HRQoL retrospectively. Of the 1,546 patients who achieved SVR, 580 achieved SVR with IFN-based treatment (SVR-IFN) and 966 achieved SVR with DAA treatment (SVR-DAA). Comparison of HRQoL before and after treatment revealed a significant increase in SVR-IFN (0.9078 vs. 0.9278, p = 0.0406). For SVR-IFN, patients in their 60s and 70s showed a significant increase in HRQoL after treatment. In contrast, changes in HRQoL in SVR-DAA were not statistically significant (0.9018 vs. 0.9063, p = 0.3908). For SVR-DAA, HRQoL significantly improved for patients in their 50s and 60s. The results of this study showed a trend toward improvement or unchanged HRQoL in patients who achieved SVR, despite advanced age. The results of this study can serve as a basis for follow-up after SVR and cost-effectiveness analyses. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Hiroshima University Medical Press |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 助成情報 |
|
|
|
助成機関名 |
日本医療研究開発機構 |
|
|
言語 |
ja |
|
|
研究課題番号 |
17fk0210104h0001 |
|
|
研究課題名 |
C型肝炎ウイルス排除後の病態、生命予後、QOLに関する包括的研究 |
|
|
言語 |
ja |
| 助成情報 |
|
|
|
助成機関名 |
Japan Agency for Medical Research and Development (AMED) |
|
|
言語 |
en |
|
|
研究課題名 |
C型肝炎ウイルス排除後の病態、生命予後、QOLに関する包括的研究 |
|
|
言語 |
ja |
| 開始ページ |
|
|
開始ページ |
1 |
| 書誌情報 |
en : Hiroshima Journal of Medical Sciences
巻 73,
号 1-2,
p. 1-7,
ページ数 7,
発行日 2024-06
|
| 旧ID |
55341 |
HiroshimaJMedSci_73_1.pdf (1.1 MB)
